Fabtech Technologies Reports Robust Q2 FY26 Results with 109.91% Revenue Growth, Targets Expansion in Bio-Pharma Sector

Fabtech Technologies Limited , a leading turnkey engineering solutions provider for the pharmaceutical and healthcare sectors, has announced impressive financial results for the second quarter of fiscal year 2026, showcasing substantial growth across key metrics. The company is also targeting rapid growth in several key areas of the bio-pharma sector.

Financial Highlights

Metric	Q2 FY26	YoY Growth
Total Income	₹12,427.61	109.91%
EBITDA	₹3,363.53	383.76%
EBITDA Margin	27.06%	1,568.59 bps
Net Profit	₹2,810.61	449.12%
Net Profit Margin	22.62%	1,423.91 bps
EPS	₹8.68	-

The company's performance for the first half of FY26 also demonstrated strong growth:

Metric	H1 FY26	YoY Growth
Total Income	₹19,322.80	101.57%
EBITDA	₹2,839.99	2,678.31%
EBITDA Margin	14.70%	1,358.72 bps
Net Profit	₹2,198.02	-
Net Profit Margin	11.38%	-47.03 bps
EPS	₹6.79	-

Operational Performance

Fabtech Technologies continues to strengthen its position in the global market:

Operations across 62 countries
Current order book of ₹90,441.87 lakhs as of July 31, 2025
78% of revenue derived from MENA, GCC, and ECO Zone markets
135 projects delivered globally

Business Overview and Growth Strategy

Fabtech Technologies Limited specializes in providing start-to-finish turnkey solutions for pharmaceutical, biotech, and healthcare facilities worldwide. The company's integrated approach covers design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments.

The company is targeting rapid growth across three key areas:

Bio-pharma equipment
Modular facilities
Engineering turnkey projects

Fabtech reports strong order visibility from vaccine manufacturing and API expansion projects. To strengthen margins and scale exports from India as a key pharma engineering hub, the company is focusing on:

Technology integration
Global partnerships
Backward integration

Market Position

The company's growth has been accelerated by the MEA region's focus on pharmaceutical self-reliance post-COVID. Fabtech's asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency, ensuring speed, quality, and consistency in project delivery.

Future Outlook

With 20 secured projects worth ₹13,724.61 lakhs, Fabtech Technologies Limited is well-positioned to continue its growth trajectory. The company's expertise in Bio-Clean Air, Pure Water, and Precision Process Systems positions it as a key player in building resilient, sustainable, and future-ready healthcare manufacturing ecosystems globally.

Fabtech Technologies Limited's strong Q2 FY26 results reflect its robust business model and strategic positioning in the pharmaceutical and healthcare engineering solutions market. The significant year-over-year growth in revenue and profitability underscores the company's ability to capitalize on the increasing demand for turnkey engineering solutions in the life sciences sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.35%	-0.45%	+27.26%	+27.26%	+27.26%	+27.26%

Fabtech Technologies Limited has announced its financial results for the first and second quarters of fiscal year 2026, showing a significant turnaround from Q1 to Q2. The company has scheduled an earnings conference call to discuss its performance.

Q1 FY26 Financial Results

For the quarter ended June 30, 2025 (Q1 FY26), Fabtech Technologies reported:

Net loss of ₹63.13 lakhs, compared to a net profit of ₹759.75 lakhs in the corresponding quarter of the previous year
Revenue from operations of ₹3,012.65 lakhs, down from ₹2,506.10 lakhs year-over-year
Basic earnings per share (EPS) turned negative at ₹2.83, compared to positive ₹3.70 in the same quarter last year

Q2 FY26 Financial Highlights

Metric	Q2 FY26	Q1 FY26	Change
Revenue from Operations	₹12,148.07 lakhs	₹6,800.68 lakhs	+78.6%
Net Profit	₹2,810.61 lakhs	(₹612.59 lakhs)	Turned Profitable
Basic EPS	₹8.68	Not Provided	N/A

H1 FY26 Performance

Revenue: ₹18,948.75 lakhs
Net Profit: ₹2,198.02 lakhs

Recent Developments

Completed IPO of 1,20,60,000 equity shares at ₹191 per share
Listed on NSE and BSE on October 7, 2025
Reported an exceptional item of ₹177.49 lakhs from sale of 51% stake in a subsidiary LLP

Earnings Call Details

Aspect	Details
Date	November 10, 2025
Time	4:00 p.m. IST
Purpose	Discussion of Q1 and Q2 FY26 Financial Results
Periods Covered	Quarter ended June 30, 2025 (Q1 FY26)
	Quarter and half-year ended September 30, 2025 (Q2 and H1 FY26)

Management Speakers

Mr. Ashwani Kumar Singh, Chief Executive Officer
Mr. Aman Anavkar, Chief Growth Officer

Participation Information

Method	Details
Universal Dial-In	+91 22 6280 1556
	+91 22 7115 8138
Diamond Pass Login	Available (details not specified)
Express Join	Click option available

New Contract Announcement

On November 3, 2025, Fabtech Technologies Limited secured a significant contract:

Contract Value: ₹52.00 crore
Project: Construction of a next-generation veterinary formulations facility in North Africa
Scope: Complete design, engineering, cleanroom systems, utilities, and process equipment

This contract has increased Fabtech's order book to ₹983.05 crore, enhancing revenue visibility and international presence.

Market Outlook

The company highlighted growth potential in the Maghreb region:

Increasing demand for livestock and companion animal health products
Growing focus on animal health management and disease prevention
Projected veterinary formulation Total Addressable Market (TAM) in the Maghreb region: USD 500-700 million by 2030

Investors and interested parties are encouraged to participate in the upcoming earnings call for more detailed insights into Fabtech Technologies' financial performance and future outlook.

Note: Forward-looking statements made during the call are subject to risks and uncertainties that could cause actual results to differ materially from those projected.